Maruthur et al. ([@B1]) showed that European genetic admixture is inversely related to HbA~1c~ levels among African Americans, although admixture explained less than 1% of the variance in HbA~1c~. Others have reported that genetic factors account for ∼60% of the variance in HbA~1c~ ([@B2]). For unclear reasons, African Americans express higher HbA~1c~ levels than Caucasians with similar blood glucose values ([@B3],[@B4]). Genetic loci that are unique to HbA~1c~ (and not necessarily shared by blood glucose) have been identified by several researchers, but specific data are lacking in African Americans ([@B5]--[@B7]). Admixture analyses, which are inherently superficial, may not provide the definitive genetic data needed to clarify black/white differences in HbA~1c~. Thus, it is premature to downplay biological differences in the etiology of ethnic disparity in HbA~1c~, or to attribute the latter to nebulous "downstream factors" ([@B1]).

Maruthur et al. report that adjusting for genetic ancestry had a minimal effect on HbA~1c~-based diagnosis of diabetes---after accounting for fasting glucose---and conclude that their findings support the use of HbA~1c~ for diagnosis of diabetes in African Americans. That conclusion is unsupported by their data: the prevalence of diabetes decreased from 11% (using HbA~1c~ ≥6.5%) to 4.4% (based on fasting glucose) ([@B1]). Thus, 60% of African Americans, who had normal fasting glucose levels, were misdiagnosed with diabetes using the recommended HbA~1c~ cutoff.

The diagnostic use of HbA~1c~ assumes a degree of concordance with blood glucose values that is simply not supported by evidence ([@B4],[@B8]). Therefore, it is desirable for clinicians to obtain confirmatory blood glucose levels when screening for diabetes or prediabetes, particularly among African Americans ([@B4]).
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